Ligand partner travere therapeutics receives full fda approval for filspari® (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in iga nephropathy

Jupiter, fla.--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) today announced that its partner travere therapeutics, inc. (nasdaq: tvtx) has received full approval from the u.s. food and drug administration (fda) for filspari® (sparsentan) to slow kidney function decline in adults with primary igan who are at risk of disease progression. ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of filspari. filspari was granted accelerated approval in.
TVTX Ratings Summary
TVTX Quant Ranking